Literature DB >> 32632776

Endothelial Progenitor Cells Induce Angiogenesis: a Potential Mechanism Underlying Neovascularization in Encephaloduroarteriosynangiosis.

Qian-Nan Wang1, Zheng-Xing Zou2, Xiao-Peng Wang2, Qian Zhang2, Ya-Qun Zhao3, Lian Duan4, Xiang-Yang Bao5.   

Abstract

Encephaloduroarteriosynangiosis (EDAS) is one of the most commonly used indirect vascular reconstruction methods. EDAS aids in the formation of collateral vessels from the extracranial to the intracranial circulation in patients with moyamoya disease (MMD). However, the underlying mechanism of collateral vessel formation is not well understood. Endothelial progenitor cells (EPCs) differentiate to form the vascular endothelial cells and play a very important role in angiogenesis. We designed this prospective clinical trial to investigate the presence of EPCs in patients with MMD and to explore the neovascularization mechanism mediated by the EPCs in EDAS. The patients who were diagnosed with MMD were recruited between February 5, 2017, and January 7, 2018. The blood samples were obtained from an antecubital vein and were analyzed using flow cytometry. EPCs were defined as CD34brCD133+CD45dimKDR+. All the patients enrolled in the study underwent EDAS. Cerebral arteriography was performed 6 months post-EDAS to assess the efficacy of synangiosis. The correlation between EPC count and good collateral circulation was evaluated. Among the 116 patients with MMD enrolled in this study, 73 were women and 43 were men. The average age of the patients was 33.8 ± 15.2 years. The EPC count of the patients with MMD was 0.071% ± 0.050% (expressed as percentage of the peripheral blood mononuclear cells). The EPC count in the good postoperative collateral circulation group was significantly higher (0.085% ± 0.054%) than that in the poor collateral circulation group (0.048% ± 0.034%) (P = 0.000). The age, modified Suzuki-Mugikura grade, and EPC count were significantly correlated with the good collateral circulation post-EDAS in the multivariate analysis (P = 0.018, P = 0.007, and P = 0.003, respectively). The formation of collateral vessels by EDAS is primarily driven by angiogenesis. The EPC count may be the most critical factor for collateral circulation. The therapeutic effect of EDAS is more likely to benefit younger or severe ischemic patients with MMD.

Entities:  

Keywords:  Angiogenesis; Encephaloduroarteriosynangiosis; Endothelial progenitor cells; Moyamoya disease

Mesh:

Year:  2020        PMID: 32632776     DOI: 10.1007/s12975-020-00834-9

Source DB:  PubMed          Journal:  Transl Stroke Res        ISSN: 1868-4483            Impact factor:   6.829


  40 in total

Review 1.  Advances and surgical considerations in the treatment of moyamoya disease.

Authors:  Eric J Arias; Colin P Derdeyn; Ralph G Dacey; Gregory J Zipfel
Journal:  Neurosurgery       Date:  2014-02       Impact factor: 4.654

2.  Insights on the revascularization mechanism for treatment of Moyamoya disease based on the histopathologic concept of angiogenesis and arteriogenesis.

Authors:  Nobuhito Saito; Hideaki Imai
Journal:  World Neurosurg       Date:  2011-02       Impact factor: 2.104

Review 3.  Mechanisms of angiogenesis.

Authors:  W Risau
Journal:  Nature       Date:  1997-04-17       Impact factor: 49.962

4.  Clinical features, surgical treatment, and long-term outcome in pediatric patients with moyamoya disease in China.

Authors:  Xiang-Yang Bao; Lian Duan; Wei-Zhong Yang; De-Sheng Li; Wei-Jian Sun; Zheng-Shan Zhang; Rui Zong; Cong Han
Journal:  Cerebrovasc Dis       Date:  2015-01-06       Impact factor: 2.762

Review 5.  Neurosurgical advances in the treatment of moyamoya disease.

Authors:  Paritosh Pandey; Gary K Steinberg
Journal:  Stroke       Date:  2011-10-06       Impact factor: 7.914

6.  Cerebrovascular "moyamoya" disease. Disease showing abnormal net-like vessels in base of brain.

Authors:  J Suzuki; A Takaku
Journal:  Arch Neurol       Date:  1969-03

7.  Clinical features, surgical treatment and long-term outcome in adult patients with Moyamoya disease in China.

Authors:  Xiang-Yang Bao; Lian Duan; De-Sheng Li; Wei-Zhong Yang; Wei-Jian Sun; Zheng-Shan Zhang; Rui Zong; Cong Han
Journal:  Cerebrovasc Dis       Date:  2012-11-08       Impact factor: 2.762

8.  Natural history of moyamoya disease: comparison of activity of daily living in surgery and non surgery groups.

Authors:  J U Choi; D S Kim; E Y Kim; K C Lee
Journal:  Clin Neurol Neurosurg       Date:  1997-10       Impact factor: 1.876

Review 9.  Moyamoya disease and moyamoya syndrome.

Authors:  R Michael Scott; Edward R Smith
Journal:  N Engl J Med       Date:  2009-03-19       Impact factor: 91.245

10.  Angiographic Structural Differentiation between Native Arteriogenesis and Therapeutic Synangiosis in Intracranial Arterial Steno-Occlusive Disease.

Authors:  Y C Ooi; A N Laiwalla; R Liou; N R Gonzalez
Journal:  AJNR Am J Neuroradiol       Date:  2016-01-21       Impact factor: 3.825

View more
  4 in total

1.  Bone mesenchymal stem cells-derived miR-223-3p-containing exosomes ameliorate lipopolysaccharide-induced acute uterine injury via interacting with endothelial progenitor cells.

Authors:  Yana Liu; Shihong Zhang; Zhiwei Xue; Xiaoxia Zhou; Lin Tong; Jiachen Liao; Huan Pan; Shu Zhou
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

2.  Adhesive, injectable, and ROS-responsive hybrid polyvinyl alcohol (PVA) hydrogel co-delivers metformin and fibroblast growth factor 21 (FGF21) for enhanced diabetic wound repair.

Authors:  Hong Zhu; Jie Xu; Min Zhao; Hangqi Luo; Minjie Lin; Yuting Luo; Yuan Li; Huacheng He; Jiang Wu
Journal:  Front Bioeng Biotechnol       Date:  2022-08-31

3.  Experimental Study on the Effect of Allogeneic Endothelial Progenitor Cells on Wound Healing in Diabetic Mice.

Authors:  Min Leng; Ying Peng; Manchang Pan; Hong Wang
Journal:  J Diabetes Res       Date:  2021-10-21       Impact factor: 4.011

Review 4.  Progression in Moyamoya Disease: Clinical Features, Neuroimaging Evaluation, and Treatment.

Authors:  Xin Zhang; Weiping Xiao; Qing Zhang; Ding Xia; Peng Gao; Jiabin Su; Heng Yang; Xinjie Gao; Wei Ni; Yu Lei; Yuxiang Gu
Journal:  Curr Neuropharmacol       Date:  2022       Impact factor: 7.708

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.